Jubilant Pharmova Limited — Updates, 31-01-2025: Press Release

Jubilant Pharmova’s recent performance highlights robust growth across multiple segments, with Q3’FY25 showing a 9% year-on-year increase in revenue, reaching ₹1,822 Cr. EBITDA rose by 11% to ₹296 Cr, supported by the successful execution of its operational strategies. Reported PAT surged 52% to ₹101 Cr, demonstrating effective cost management and improved operating efficiency.

The Radiopharma segment thrived, with revenue climbing 10% to ₹265 Cr, buoyed by the successful distribution of PYLARIFY® and positive traction from new products like Sulfur Colloid. The Allergy Immunotherapy division achieved a 7% revenue uptick to ₹171 Cr, overcoming production challenges that had previously affected margins.

CDMO Sterile Injectables remained stable at ₹306 Cr in revenue, boosted by ongoing capacity expansion at its Spokane facility. The CRDMO sector showed strong momentum, driven by new contracts with major pharmaceutical clients, with Drug Discovery revenues increasing 32% to ₹150 Cr.

Looking ahead, Jubilant Pharmova's strategic investment of $50 million to expand its PET radiopharmacy network underscores its commitment to future growth while maintaining a positive outlook across all business units. Investors should monitor the company closely as it positions itself to capitalize on growth opportunities in the evolving pharmaceutical landscape.